Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
My Portfolio
Articles published by Enterprise Therapeutics Ltd
Enterprise Therapeutics Granted EMA Orphan Medicinal Product Designation for Novel Cystic Fibrosis Therapy, ETD001
Today 4:00 EST
From
Enterprise Therapeutics Ltd
Via
Business Wire
Enterprise Therapeutics Achieves Primary Efficacy Outcome in Phase 2 Clinical Trial for Cystic Fibrosis With Novel Inhaled ENaC Blocker ETD001
May 12, 2026
From
Enterprise Therapeutics Ltd
Via
Business Wire
Enterprise Therapeutics publishes results of Phase 1 study of ETD001, a novel inhaled ENaC blocker for treatment of Cystic Fibrosis, in The Journal of Cystic Fibrosis
December 09, 2025
From
Enterprise Therapeutics Ltd
Via
Business Wire
Enterprise Therapeutics Granted ‘Rare Pediatric Disease Designation’ in the US for Novel Cystic Fibrosis Investigational Therapy ETD001
September 26, 2024
From
Enterprise Therapeutics Ltd
Via
Business Wire
Enterprise Therapeutics doses first subjects in Phase I trial for novel cystic fibrosis therapy ETD001
June 14, 2021
From
Enterprise Therapeutics Ltd
Via
Business Wire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.